{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:22:38Z","timestamp":1760908958334},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s10689-016-9873-9","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T08:41:22Z","timestamp":1454316082000},"page":"497-506","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis"],"prefix":"10.1007","volume":"15","author":[{"given":"Renaud","family":"Sabatier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Lavit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lambaudie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Eisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Cherau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Provansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doriane","family":"Livon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Rabayrol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornel","family":"Popovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Charaffe-Jauffret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagay","family":"Sobol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Viens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"9873_CR1","unstructured":"Binder-Foucard F, Belot A, Delafosse P, et al. (2013) Estimation nationale de l\u2019incidence et de la mortalit\u00e9 par cancer en France entre 1980 et 2012. Partie 1\u2014Tumeurs solides. Institut de veille sanitaire"},{"key":"9873_CR2","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.12968\/bjon.2013.22.Sup17.S23","volume":"22","author":"C Rooth","year":"2013","unstructured":"Rooth C (2013) Ovarian cancer: risk factors, treatment and management. Br J Nurs Mark Allen Publ 22:S23\u2013S30","journal-title":"Br J Nurs Mark Allen Publ"},{"key":"9873_CR3","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1634\/theoncologist.2012-0028","volume":"17","author":"G Rigakos","year":"2012","unstructured":"Rigakos G, Razis E (2012) BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 17:956\u2013962. doi: 10.1634\/theoncologist.2012-0028","journal-title":"Oncologist"},{"key":"9873_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1684\/bdc.2012.1544","volume":"99","author":"A Pauw de","year":"2012","unstructured":"de Pauw A, Jolissaint L, Fr\u00e9neaux P et al (2012) Hereditary forms of ovarian cancer. Bull Cancer (Paris) 99:453\u2013462. doi: 10.1684\/bdc.2012.1544","journal-title":"Bull Cancer (Paris)"},{"key":"9873_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.humpath.2005.06.006","volume":"36","author":"J Prat","year":"2005","unstructured":"Prat J, Rib\u00e9 A, Gallardo A (2005) Hereditary ovarian cancer. Hum Pathol 36:861\u2013870. doi: 10.1016\/j.humpath.2005.06.006","journal-title":"Hum Pathol"},{"key":"9873_CR6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117\u20131130","journal-title":"Am J Hum Genet"},{"key":"9873_CR7","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"MS Brose","year":"2002","unstructured":"Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365\u20131372","journal-title":"J Natl Cancer Inst"},{"key":"9873_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329\u20131333. doi: 10.1200\/JCO.2006.09.1066","journal-title":"J Clin Oncol"},{"key":"9873_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","volume":"22","author":"PMLH Vencken","year":"2011","unstructured":"Vencken PMLH, Kriege M, Hoogwerf D et al (2011) Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 22:1346\u20131352. doi: 10.1093\/annonc\/mdq628","journal-title":"Ann Oncol"},{"key":"9873_CR10","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","volume":"26","author":"DSP Tan","year":"2008","unstructured":"Tan DSP, Rothermundt C, Thomas K et al (2008) \u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530\u20135536. doi: 10.1200\/JCO.2008.16.1703","journal-title":"J Clin Oncol"},{"key":"9873_CR11","first-page":"235","volume":"4","author":"H Aida","year":"1998","unstructured":"Aida H, Takakuwa K, Nagata H et al (1998) Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4:235\u2013240","journal-title":"Clin Cancer Res"},{"key":"9873_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ygyno.2010.12.354","volume":"121","author":"RA Lacour","year":"2011","unstructured":"Lacour RA, Westin SN, Meyer LA et al (2011) Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121:358\u2013363. doi: 10.1016\/j.ygyno.2010.12.354","journal-title":"Gynecol Oncol"},{"key":"9873_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"KL Bolton","year":"2012","unstructured":"Bolton KL, Chenevix-Trench G, Goh C et al (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382\u2013390. doi: 10.1001\/jama.2012.20","journal-title":"JAMA"},{"key":"9873_CR14","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1002\/cncr.26655","volume":"118","author":"DM Hyman","year":"2012","unstructured":"Hyman DM, Zhou Q, Iasonos A et al (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703\u20133709. doi: 10.1002\/cncr.26655","journal-title":"Cancer"},{"key":"9873_CR15","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654\u20132663. doi: 10.1200\/JCO.2011.39.8545","journal-title":"J Clin Oncol"},{"key":"9873_CR16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.20.2.463","volume":"20","author":"Y Ben David","year":"2002","unstructured":"Ben David Y, Chetrit A, Hirsh-Yechezkel G et al (2002) Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20:463\u2013466","journal-title":"J Clin Oncol"},{"key":"9873_CR17","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/annonc\/mdq577","volume":"22","author":"DJ Gallagher","year":"2011","unstructured":"Gallagher DJ, Konner JA, Bell-McGuinn KM et al (2011) Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol 22:1127\u20131132. doi: 10.1093\/annonc\/mdq577","journal-title":"Ann Oncol"},{"key":"9873_CR18","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","volume":"283","author":"J Boyd","year":"2000","unstructured":"Boyd J, Sonoda Y, Federici MG et al (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260\u20132265","journal-title":"JAMA"},{"key":"9873_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","volume":"26","author":"A Chetrit","year":"2008","unstructured":"Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al (2008) Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26:20\u201325. doi: 10.1200\/JCO.2007.11.6905","journal-title":"J Clin Oncol"},{"key":"9873_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","volume":"21","author":"Q Zhong","year":"2015","unstructured":"Zhong Q, Peng H-L, Zhao X et al (2015) Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 21:211\u2013220. doi: 10.1158\/1078-0432.CCR-14-1816","journal-title":"Clin Cancer Res"},{"key":"9873_CR21","doi-asserted-by":"publisher","first-page":"e95285","DOI":"10.1371\/journal.pone.0095285","volume":"9","author":"C Sun","year":"2014","unstructured":"Sun C, Li N, Ding D et al (2014) The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One 9:e95285. doi: 10.1371\/journal.pone.0095285","journal-title":"PLoS One"},{"key":"9873_CR22","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/IGC.0000000000000247","volume":"24","author":"V Rudaitis","year":"2014","unstructured":"Rudaitis V, Zvirblis T, Kanopiene D et al (2014) BRCA1\/2 mutation status is an independent factor of improved survival for advanced (stage III\u2013IV) ovarian cancer. Int J Gynecol Cancer 24:1395\u20131400. doi: 10.1097\/IGC.0000000000000247","journal-title":"Int J Gynecol Cancer"},{"key":"9873_CR23","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A (2004) Hallmarks of \u201cBRCAness\u201d in sporadic cancers. Nat Rev Cancer 4:814\u2013819. doi: 10.1038\/nrc1457","journal-title":"Nat Rev Cancer"},{"key":"9873_CR24","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","volume":"28","author":"BTJ Hennessy","year":"2010","unstructured":"Hennessy BTJ, Timms KM, Carey MS et al (2010) Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28:3570\u20133576. doi: 10.1200\/JCO.2009.27.2997","journal-title":"J Clin Oncol"},{"key":"9873_CR25","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1200\/JCO.2007.11.3902","volume":"26","author":"JI Weberpals","year":"2008","unstructured":"Weberpals JI, Clark-Knowles KV, Vanderhyden BC (2008) Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 26:3259\u20133267. doi: 10.1200\/JCO.2007.11.3902","journal-title":"J Clin Oncol"},{"key":"9873_CR26","first-page":"5329","volume":"60","author":"RL Baldwin","year":"2000","unstructured":"Baldwin RL, Nemeth E, Tran H et al (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329\u20135333","journal-title":"Cancer Res"},{"key":"9873_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10689-015-9786-z","volume":"14","author":"MT Vietri","year":"2015","unstructured":"Vietri MT, Caliendo G, Schiano C et al (2015) Analysis of PALB2 in a cohort of Italian breast cancer patients: identification of a novel PALB2 truncating mutation. Fam Cancer 14:341\u2013348. doi: 10.1007\/s10689-015-9786-z","journal-title":"Fam Cancer"},{"key":"9873_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10689-012-9523-9","volume":"11","author":"W Lu","year":"2012","unstructured":"Lu W, Wang X, Lin H et al (2012) Mutation screening of RAD51C in high-risk breast and ovarian cancer families. Fam Cancer 11:381\u2013385. doi: 10.1007\/s10689-012-9523-9","journal-title":"Fam Cancer"},{"key":"9873_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI et al (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764\u2013775. doi: 10.1158\/1078-0432.CCR-13-2287","journal-title":"Clin Cancer Res"},{"key":"9873_CR30","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1038\/ncomms4156","volume":"5","author":"KL Kanchi","year":"2014","unstructured":"Kanchi KL, Johnson KJ, Lu C et al (2014) Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 5:3156. doi: 10.1038\/ncomms4156","journal-title":"Nat Commun"},{"key":"9873_CR31","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/94.18.1396","volume":"94","author":"JL Hilton","year":"2002","unstructured":"Hilton JL, Geisler JP, Rathe JA et al (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94:1396\u20131406","journal-title":"J Natl Cancer Inst"},{"key":"9873_CR32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/gcc.20822","volume":"49","author":"R Sabatier","year":"2010","unstructured":"Sabatier R, Ad\u00e9la\u00efde J, Finetti P et al (2010) BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes Chromosomes Cancer 49:1143\u20131151. doi: 10.1002\/gcc.20822","journal-title":"Genes Chromosomes Cancer"},{"key":"9873_CR33","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","volume":"28","author":"PA Konstantinopoulos","year":"2010","unstructured":"Konstantinopoulos PA, Spentzos D, Karlan BY et al (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555\u20133561. doi: 10.1200\/JCO.2009.27.5719","journal-title":"J Clin Oncol"},{"key":"9873_CR34","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1200\/JCO.2002.05.121","volume":"20","author":"DA Berry","year":"2002","unstructured":"Berry DA, Iversen ES, Gudbjartsson DF et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1\/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701\u20132712","journal-title":"J Clin Oncol"},{"key":"9873_CR35","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/jmg.2003.017996","volume":"41","author":"DGR Evans","year":"2004","unstructured":"Evans DGR, Eccles DM, Rahman N et al (2004) A new scoring system for the chances of identifying a BRCA1\/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41:474\u2013480","journal-title":"J Med Genet"},{"key":"9873_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371:497\u2013506. doi: 10.1056\/NEJMoa1400382","journal-title":"N Engl J Med"},{"key":"9873_CR37","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 4:e297. doi: 10.1371\/journal.pmed.0040297","journal-title":"PLoS Med"},{"key":"9873_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cancergen.2012.01.008","volume":"205","author":"J Liu","year":"2012","unstructured":"Liu J, Cristea MC, Frankel P et al (2012) Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): genotype and survival. Cancer Genet 205:34\u201341. doi: 10.1016\/j.cancergen.2012.01.008","journal-title":"Cancer Genet"},{"key":"9873_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000353786","volume":"85","author":"D Lorusso","year":"2013","unstructured":"Lorusso D, Cirillo F, Mancini M et al (2013) The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience. Oncology 85:122\u2013127. doi: 10.1159\/000353786","journal-title":"Oncology"},{"key":"9873_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2147\/IJWH.S40894","volume":"6","author":"K Doufekas","year":"2014","unstructured":"Doufekas K, Olaitan A (2014) Clinical epidemiology of epithelial ovarian cancer in the UK. Int J Womens Health 6:537\u2013545. doi: 10.2147\/IJWH.S40894","journal-title":"Int J Womens Health"},{"key":"9873_CR41","first-page":"658","volume":"31","author":"G Artioli","year":"2010","unstructured":"Artioli G, Borgato L, Cappetta A et al (2010) Overall survival in BRCA-associated ovarian cancer: case-control study of an Italian series. Eur J Gynaecol Oncol 31:658\u2013661","journal-title":"Eur J Gynaecol Oncol"},{"key":"9873_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1\u20136. doi: 10.1056\/NEJM199601043340101","journal-title":"N Engl J Med"},{"key":"9873_CR43","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21:3194\u20133200. doi: 10.1200\/JCO.2003.02.153","journal-title":"J Clin Oncol"},{"key":"9873_CR44","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943\u2013953. doi: 10.1056\/NEJMoa0908806","journal-title":"N Engl J Med"},{"key":"9873_CR45","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1200\/JCO.2012.45.0940","volume":"31","author":"G Minckwitz von","year":"2013","unstructured":"von Minckwitz G, Blohmer JU, Costa SD et al (2013) Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 31:3623\u20133630. doi: 10.1200\/JCO.2012.45.0940","journal-title":"J Clin Oncol"},{"key":"9873_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejogrb.2009.07.016","volume":"147","author":"J-G Ferron","year":"2009","unstructured":"Ferron J-G, Uzan C, Rey A et al (2009) Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease. Eur J Obstet Gynecol Reprod Biol 147:101\u2013105. doi: 10.1016\/j.ejogrb.2009.07.016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"9873_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00404-009-1330-7","volume":"282","author":"A Bilici","year":"2010","unstructured":"Bilici A, Salepci T, Dane F et al (2010) Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience. Arch Gynecol Obstet 282:417\u2013425. doi: 10.1007\/s00404-009-1330-7","journal-title":"Arch Gynecol Obstet"},{"key":"9873_CR48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0301-2115(01)00318-9","volume":"98","author":"RP Zweemer","year":"2001","unstructured":"Zweemer RP, Verheijen RH, Coebergh JW et al (2001) Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol 98:219\u2013223","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"9873_CR49","first-page":"1196","volume":"8","author":"RE Buller","year":"2002","unstructured":"Buller RE, Shahin MS, Geisler JP et al (2002) Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 8:1196\u20131202","journal-title":"Clin Cancer Res"},{"key":"9873_CR50","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.1998.16.2.397","volume":"16","author":"OT J\u00f3hannsson","year":"1998","unstructured":"J\u00f3hannsson OT, Ranstam J, Borg A, Olsson H (1998) Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16:397\u2013404","journal-title":"J Clin Oncol"},{"key":"9873_CR51","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/cncr.11310","volume":"97","author":"I Cass","year":"2003","unstructured":"Cass I, Baldwin RL, Varkey T et al (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187\u20132195. doi: 10.1002\/cncr.11310","journal-title":"Cancer"},{"key":"9873_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/ejso.2000.1097","volume":"27","author":"SJ Ramus","year":"2001","unstructured":"Ramus SJ, Fishman A, Pharoah PD et al (2001) Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol 27:278\u2013281. doi: 10.1053\/ejso.2000.1097","journal-title":"Eur J Surg Oncol"},{"key":"9873_CR53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2407-5-134","volume":"5","author":"P Kringen","year":"2005","unstructured":"Kringen P, Wang Y, Dumeaux V et al (2005) TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. BMC Cancer 5:134. doi: 10.1186\/1471-2407-5-134","journal-title":"BMC Cancer"},{"key":"9873_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10689-006-9112-x","volume":"6","author":"T Pal","year":"2007","unstructured":"Pal T, Permuth-Wey J, Kapoor R et al (2007) Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 6:113\u2013119. doi: 10.1007\/s10689-006-9112-x","journal-title":"Fam Cancer"},{"key":"9873_CR55","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","volume":"125","author":"RB Dann","year":"2012","unstructured":"Dann RB, DeLoia JA, Timms KM et al (2012) BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 125:677\u2013682. doi: 10.1016\/j.ygyno.2012.03.006","journal-title":"Gynecol Oncol"},{"key":"9873_CR56","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917\u2013921. doi: 10.1038\/nature03445","journal-title":"Nature"},{"key":"9873_CR57","first-page":"551","volume":"34","author":"F Muggia","year":"2014","unstructured":"Muggia F, Safra T (2014) \u201cBRCAness\u201d and its implications for platinum action in gynecologic cancer. Anticancer Res 34:551\u2013556","journal-title":"Anticancer Res"},{"key":"9873_CR58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-31-87","volume":"31","author":"R Sabatier","year":"2012","unstructured":"Sabatier R, Gon\u00e7alves A, Bertucci F et al (2012) Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res CR 31:87. doi: 10.1186\/1756-9966-31-87","journal-title":"J Exp Clin Cancer Res CR"},{"key":"9873_CR59","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A et al (2011) Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305:2295\u20132303. doi: 10.1001\/jama.2011.766","journal-title":"JAMA"},{"key":"9873_CR60","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ygyno.2013.06.029","volume":"130","author":"CJ Reade","year":"2013","unstructured":"Reade CJ, Riva JJ, Busse JW et al (2013) Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 130:674\u2013681. doi: 10.1016\/j.ygyno.2013.06.029","journal-title":"Gynecol Oncol"},{"key":"9873_CR61","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10549-011-1677-x","volume":"130","author":"M Vuorela","year":"2011","unstructured":"Vuorela M, Pylk\u00e4s K, Hartikainen JM et al (2011) Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat 130:1003\u20131010. doi: 10.1007\/s10549-011-1677-x","journal-title":"Breast Cancer Res Treat"},{"key":"9873_CR62","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-Positive and BRCA-negative breast cancer. J Clin Oncol 26:4282\u20134288. doi: 10.1200\/JCO.2008.16.6231","journal-title":"J Clin Oncol"},{"key":"9873_CR63","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ygyno.2014.05.028","volume":"134","author":"E Lokich","year":"2014","unstructured":"Lokich E, Stuckey A, Raker C et al (2014) Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol 134:326\u2013330. doi: 10.1016\/j.ygyno.2014.05.028","journal-title":"Gynecol Oncol"},{"key":"9873_CR64","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","volume":"25","author":"WE Winter","year":"2007","unstructured":"Winter WE, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol 25:3621\u20133627. doi: 10.1200\/JCO.2006.10.2517","journal-title":"J Clin Oncol"},{"key":"9873_CR65","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.1989.7.6.769","volume":"7","author":"JC Houwelingen van","year":"1989","unstructured":"van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME et al (1989) Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol 7:769\u2013773","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"9873_CR66","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123\u2013134. doi: 10.1056\/NEJMoa0900212","journal-title":"N Engl J Med"},{"key":"9873_CR67","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852\u2013861. doi: 10.1016\/S1470-2045(14)70228-1","journal-title":"Lancet Oncol"},{"key":"9873_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO et al (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16:87\u201397. doi: 10.1016\/S1470-2045(14)71135-0","journal-title":"Lancet Oncol"},{"key":"9873_CR69","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ygyno.2014.02.039","volume":"133","author":"JF Liu","year":"2014","unstructured":"Liu JF, Konstantinopoulos PA, Matulonis UA (2014) PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol 133:362\u2013369. doi: 10.1016\/j.ygyno.2014.02.039","journal-title":"Gynecol Oncol"},{"key":"9873_CR70","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"Liu JF, Barry WT, Birrer M et al (2014) Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 15:1207\u20131214. doi: 10.1016\/S1470-2045(14)70391-2","journal-title":"Lancet Oncol"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-016-9873-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-016-9873-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-016-9873-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T21:46:17Z","timestamp":1559252777000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-016-9873-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["9873"],"URL":"https:\/\/doi.org\/10.1007\/s10689-016-9873-9","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}